ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Revealing the prognostic landscape of hemoglobin, albumin, lymphocyte, and platelet score in patients with lung cancer: a pooled analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been reported to be associated with the progression and prognosis of various malignancies. However, its prognostic significance in patients with lung cancer remains controversial.
methodsWe conducted a systematic evaluation to investigate the prognostic value of the HALP score in relation to survival outcomes in patients with lung cancer. A comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library was performed up to October, 2025, to identify studies assessing the association between HALP and lung cancer prognosis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated for overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS).
resultsA total of 17 studies involving 10,635 lung cancer patients were included. Specifically, 15 studies (10,238 patients) assessed OS, 6 studies (1173 patients) assessed PFS, and 3 studies (362 patients) assessed DFS/RFS. The pooled analysis revealed that a low HALP score was significantly associated with poorer OS (HR 1.82, 95%CI 1.46-2.28, p < 0.001), PFS (HR 1.66, 95%CI 1.17-2.35, p < 0.001), and DFS/RFS (HR 2.78, 95%CI 1.14-6.78, p < 0.001). Subgroup analyses further confirmed that pretreatment HALP was an independent predictor of OS in lung cancer patients.
conclusionsA lower pretreatment HALP score was significantly associated with poorer prognosis in patients with lung cancer. Although HALP may represent a promising and easily accessible prognostic biomarker, its clinical application is currently constrained by substantial cut-off heterogeneity and the lack of externally validated thresholds. Future large-scale prospective studies should establish standardized cut-off values and evaluate HALP as part of integrated prognostic models.
Indexed as
Identifiers
42315819What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.